← SynDRA
lutetium (177Lu) vipivotide tetraxetan
SynDRA canonical compound SYN0041312 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | FOLH1 |
|---|
| Mechanism of action | glutamate carboxypeptidase inhibitor |
|---|
| Indication | prostate cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- FOLH1 BINDING AGENT
- Glutamate carboxypeptidase II binding agent
- glutamate carboxypeptidase inhibitor
- KLK3 BINDING AGENT
Drug classes
- Diagnostic Uses of Chemicals
- Indicators and Reagents
- Radiopharmaceuticals
ATC classes
- V10X · OTHER THERAPEUTIC RADIOPHARMACEUTICALS
Cross-references
Synonyms
- pluvicto
- 177Lu-PSMA-617
- JK-218
- Vipivotide tetraxetan
- Vipivotida tetraxetan
- DKFZ-PSMA-617
- PSMA-617
- PSMA617
- JBHPLHATEXGMQR-VLOIPPKDSA-N
- UNII-4YM1W0EGQ5
- 4YM1W0EGQ5
- SCHEMBL20180896
- HY-117410
- CS-0065894
- Lutetium Lu-177 vipivotide tetraxetan
- G6UF363ECX
- Vipivotide tetraxetan Lu-177
- PSMA-617 Lu-177
- UNII-G6UF363ECX
- Vipivotide tetraxetan lutetium Lu-177
- lutetium lu 177 vipivotide tetraxetan [USAN]
- WHO 11429
- PLUVICTO
- SCHEMBL29361946
- lutetium ((1)Lu) vipivotide tetraxetan [INN]
- Lutetium (177Lu) vipivotide tetraxetan [INN]
- LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN [WHO-DD]
- PSMA617 TFA
- Vipivotide tetraxetan [INN]
- Vipivotide tetraxetan [USAN]
- Vipivotide tetraxetan (PSMA-617)
- orb1309212
- SCHEMBL21316439
- SCHEMBL21501570
- SCHEMBL29362355
- SCHEMBL29648484
- GTPL11982
- PSMA-617?
Look up lutetium (177Lu) vipivotide tetraxetan in the interactive SynDRA portal →